» Articles » PMID: 34321660

Structural Basis of Ketamine Action on Human NMDA Receptors

Overview
Journal Nature
Specialty Science
Date 2021 Jul 29
PMID 34321660
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Ketamine is a non-competitive channel blocker of N-methyl-D-aspartate (NMDA) receptors. A single sub-anaesthetic dose of ketamine produces rapid (within hours) and long-lasting antidepressant effects in patients who are resistant to other antidepressants. Ketamine is a racemic mixture of S- and R-ketamine enantiomers, with S-ketamine isomer being the more active antidepressant. Here we describe the cryo-electron microscope structures of human GluN1-GluN2A and GluN1-GluN2B NMDA receptors in complex with S-ketamine, glycine and glutamate. Both electron density maps uncovered the binding pocket for S-ketamine in the central vestibule between the channel gate and selectivity filter. Molecular dynamics simulation showed that S-ketamine moves between two distinct locations within the binding pocket. Two amino acids-leucine 642 on GluN2A (homologous to leucine 643 on GluN2B) and asparagine 616 on GluN1-were identified as key residues that form hydrophobic and hydrogen-bond interactions with ketamine, and mutations at these residues reduced the potency of ketamine in blocking NMDA receptor channel activity. These findings show structurally how ketamine binds to and acts on human NMDA receptors, and pave the way for the future development of ketamine-based antidepressants.

Citing Articles

Green procedures for synthesizing potential NMDA receptor allosteric modulators through reduction and one-pot reductive acetylation of nitro(hetero)arenes using a superparamagnetic FeO@APTMS@CpZrCl nanocatalyst.

Mousavi H, Zeynizadeh B, Sepehraddin F Nanoscale Adv. 2025; .

PMID: 40070439 PMC: 11892742. DOI: 10.1039/d4na00882k.


The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.

You Z, Lan X, Wang C, Liu H, Li W, Mai S CNS Neurosci Ther. 2025; 31(3):e70324.

PMID: 40059071 PMC: 11890978. DOI: 10.1111/cns.70324.


An antidepressant mechanism underlying the allosteric inhibition of GluN2D-incorporated NMDA receptors at GABAergic interneurons.

Zhang J, Duan J, Li W, Wang X, Ren S, Ye L Sci Adv. 2025; 11(10):eadq0444.

PMID: 40043126 PMC: 11881904. DOI: 10.1126/sciadv.adq0444.


Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?.

Levinstein M, Budinich R, Bonaventura J, Schatzberg A, Zarate Jr C, Michaelides M Am J Psychiatry. 2025; 182(3):247-258.

PMID: 39810555 PMC: 11872000. DOI: 10.1176/appi.ajp.20240378.


Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment.

Antos Z, Zukow X, Bursztynowicz L, Jakubow P Int J Mol Sci. 2025; 25(24.

PMID: 39769420 PMC: 11728282. DOI: 10.3390/ijms252413658.


References
1.
Autry A, Adachi M, Nosyreva E, Na E, Los M, Cheng P . NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475(7354):91-5. PMC: 3172695. DOI: 10.1038/nature10130. View

2.
Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D . Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4):351-4. DOI: 10.1016/s0006-3223(99)00230-9. View

3.
Fava M, Freeman M, Flynn M, Judge H, Hoeppner B, Cusin C . Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018; 25(7):1592-1603. PMC: 6447473. DOI: 10.1038/s41380-018-0256-5. View

4.
Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg F . Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol. 1997; 333(1):99-104. DOI: 10.1016/s0014-2999(97)01116-3. View

5.
Malhi G, Mann J . Depression. Lancet. 2018; 392(10161):2299-2312. DOI: 10.1016/S0140-6736(18)31948-2. View